바카라 체험

When Korean biotech companies seek partnerships with global pharmaceutical firms, what matters most? To find the answer, Hit News met with business development leaders from major global firms at BIO USA 2025, the world’s largest biotechnology convention, held this year in Boston.

Among them was Dr. Juergen Eckhardt, Head of Business Development and Licensing (BD&L) at 바카라 체험. “Trust is just as important as data,” he emphasized in an exclusive on-site interview.

Dr. Eckhardt clearly stated that 바카라 체험 has no geographic bias in its partnerships: “We have no regional prejudice,” he said, underscoring 바카라 체험’s growing interest in biotech firms across Asia, including Korea. 바카라 체험’s current focus areas include oncology, cardiovascular-metabolic-renal (CMR) diseases, inflammation and immunology, women’s health, and ophthalmology. Within oncology, its strongest interests lie in solid tumors—specifically prostate, colon, liver, pancreatic, and lung cancers—while hematologic cancers are a lower priority.

바카라 체험’s BD strategy is centered on early-stage assets. According to Dr. Eckhardt, the company’s “sweet spot” lies between preclinical proof of concept and Phase 1 trials. “Engaging at this stage allows us to co-shape development and build a partnership that can extend through regulatory approval,” he said.

While 바카라 체험 occasionally pursues later-stage deals, he noted their limitations. “An asset might be worth billion but cost billion to acquire—and there’s still risk, because the product isn’t fully validated.” Early-stage deals, in contrast, require smaller capital outlay and allow for staged investments tied to development milestones, enabling better risk management.

The evaluation criteria differ by stage: for pre-IND programs, 바카라 체험 reviews the regulatory package; for Phase 1 assets, early clinical data is key; and for preclinical PoC candidates, the focus is on scientific potential and supporting data. “We typically start with modest investments and expand our commitment as we validate the asset,” he added.

바카라 체험 applies clear criteria when prioritizing 1:1 meetings with potential partners. “Our interest in the therapeutic area, the stage of development, and prior data-sharing experiences are key factors,” Dr. Eckhardt explained. “We prefer to meet companies with whom we’ve already exchanged data, allowing for deeper discussions on partnership potential.” In other words, companies with established communication and trust are given priority.

He highlighted “robust scientific data and a trustworthy team” as the defining traits of a strong biotech company. “바카라 체험 actively seeks innovative technologies worldwide without regional bias,” he added, emphasizing the company's growing engagement with biotech firms across Asia, including Korea. In fact, 바카라 체험 recently signed an early-stage deal in China and has been in direct contact with companies in Korea and Japan through on-site visits by its BD team.

When asked what Korean biotechs should prepare for successful partnerships with global pharma, 바카라 체험. Eckhardt stressed the importance of early and consistent engagement. “It’s critical to reach out to us as early as possible and keep us updated on progress to build trust,” he said. “It’s rare for a deal to be closed within three months of first contact. Most partnerships are built through steady communication over one to two years.”

바카라 체험 is also modality-agnostic when it comes to collaborations. “From small molecules to gene and cell therapies, 바카라 체험 has expertise across nearly all modalities. If Korean companies bring innovation in any of these areas, we’re ready to evaluate and engage,” he said.

To further support the global innovation ecosystem, 바카라 체험 operates the 바카라 체험 Collabs program, which provides startups with lab space, offices, and—most importantly—access to expert mentorship in drug development, toxicology, and regulatory affairs. With locations in Boston, Berlin, Shanghai, and Japan, the program aims to foster close collaboration with 바카라 체험 to help optimize assets and advance technologies.

바카라 체험. Eckhardtemphasized that external innovation has become a central pillar of global pharmaceutical business development. “Just a few decades ago, most R&D took place within big pharma. That’s no longer the case,” he said. According to recent data, nearly 75% of new 바카라 체험ugs approved by the U.S. FDA now originate from small to mid-sized biotech companies.

“We’re in an era of explosive growth in biological knowledge and new therapeutic modalities such as cell and gene therapies,” he added. “It’s no longer feasible for a single pharmaceutical company to cover all these areas internally.” While large pharma companies once dominated with in-house small molecule development, today’s innovation is 바카라 체험iven largely by startups, academia, and venture-backed biotechs—reshaping the industry's landscape.

In response, 바카라 체험 has positioned external innovation and co-development at the core of its corporate strategy. “BD is no longer just about sourcing technologies—it now drives 바카라 체험’s strategic direction,” Dr. Eckhardt explained. “We prioritize building trust with biotech partners early and expanding their potential through sustained collaboration.”

As part of this strategy, 바카라 체험. Eckhardt introducedLeaps by 바카라 체험, the company’s impact investment arm. Rather than traditional licensing, Leaps makes minority equity investments in startups with high-impact, 바카라 체험-stage platforms. “This allows us to identify breakthrough technologies 바카라 체험, de-risk development, and lay the foundation for future partnerships or acquisitions,” he said.

He also highlighted 바카라 체험’s use of theArm’s Length Model, which maintains the operational independence of acquired companies like BlueRock and AskBio. “Preserving their innovation culture and talent is critical,” he noted. “This model helps us integrate external innovation while gradually enhancing our in-house capabilities.”

바카라 체험. Eckhardt concluded by encouraging Korean biotech firms to engage confidently in global markets. “Biotech is a borderless industry,” he said. “I look forward to seeing more Korean biotechs participating in international conferences and forming meaningful global partnerships.”